The Crucial Roles of Different Insulin Therapies: From Short-Acting to Ultra-Long-Acting Analogs
DOI:
https://doi.org/10.58445/rars.3498Keywords:
insulin therapy, rapid-acting insulin, ultra-long-acting insulin, diabetes treatment strategies, glucose control, basal and bolus insulin, insulin analogs, pharmacokinetics, pharmacodynamicsAbstract
Diabetes is a global disease that is characterized by ongoing high blood glucose levels due to defective insulin production and/or body insulin resistance, or a combination of both. People with type 1 diabetes and those with type 2 diabetes who experience beta-cell function deterioration need insulin therapy as their main treatment option. Modern insulin analogs follow natural body insulin patterns to provide better blood glucose management and protect patients from developing complications. The post-meal glucose regulation of rapid-acting analogs aligns with their targeted action while long-acting and ultra-long-acting formulations provide stable basal coverage with minimal glycemic fluctuations and a decrease in hypoglycemic events. The development of once-weekly basal insulin represents a novel treatment approach that enhances patient compliance by reducing the frequency of injections. The treatment of type 2 diabetes faces ongoing challenges because of hypoglycemia risks, weight fluctuations, high expenses, and limited long-term availability. This review paper aims to examine distinct types of insulin, ranging from short-acting to long-acting insulin analogs, alongside new insulin approaches, to determine their clinical applications, benefits, and drawbacks for personalized diabetes treatment. The future of diabetes treatment depends on the ongoing development of new insulin products and delivery methods, as well as affordable pricing solutions.
References
1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S19–S40.
2. International Diabetes Federation. IDF Diabetes Atlas (10th ed.) [Internet]. Brussels, Belgium: International Diabetes Federation; 2023. Available from: https://idf.org
3. Hu FB. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–57.
4. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
5. American Diabetes Association. Insulin Basics.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837–53.
7. Philis-Tsimikas A, Asong M, Franek E, Jia T, Rosenstock J, Stachlewska K, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open-label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11(6):414–25.
8. Shetty S, Suvarna R. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials. Diabetes Obes Metab. 2024;26(3):1069–81.
9. Bode BW, others. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal–bolus regimen for type 2 diabetes. Diabetes Obes Metab. 2011;13(9):893–900.
10. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther [Internet]. 2016;18(S1):S29–S36. Available from: https://doi.org/10.1089/dia.2015.0343
11. National Library of Medicine. Insulin and Glucagon – Blood glucose Control.
12. Chawla R. Insulin actions in main insulin-sensitive tissues. 2014.
13. Heinemann L, Weyer C. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet. 2002;41(10):841–59.
14. Bekiari E, Avgerinos I, Liakos A, Rojas-Garcia A, Elliott J, Misso M, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ [Internet]. 2018;361:k1310. Available from: https://doi.org/10.1136/bmj.k1310
15. Luzio SD, others. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. Diabetes Technol Ther. 2020;22(8):598–606.
16. Plum-Mörschel L, Heise T, Becker RH, others. Comparative pharmacology of short-acting human insulin and rapid-acting analogues. Clin Pharmacokinet [Internet]. 2022;61(2):259–73. Available from: https://doi.org/10.1007/s40262-021-01050-8
17. Heise T, Mathieu C. Impact of insulin formulation on pharmacokinetics and pharmacodynamics: Focus on intermediate-acting insulin. Diabetes Obes Metab [Internet]. 2015;17(S1):15–24. Available from: https://doi.org/10.1111/dom.12472
18. Riddle MC, others. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients (Treat-to-Target Trial). Diabetes Care. 2003;26(11):3080–6.
19. Mordor A, others. Oral insulin delivery: how far are we? Diabetes Obes Metab. 2013;15(3):205–12.
20. Garber AJ, others. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1). The Lancet. 2012;379(9825):1489–97.
21. Hövelmann U, Zinman B, Bøttcher SG, Bailey TS, Hansen AK, Plum-Mörschel L. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes mellitus. Diabetes Obes Metab. 2023;25(3):689–97.
22. Lingvay I, Catarig AM, Frias JP, Kumar A, Lausvig NL, le Roux CW, et al. Efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combinations in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab [Internet]. 2021;23(4):870–82. Available from: https://doi.org/10.1111/dom.14287
23. Maiorino MI, others. GLP-1 receptor agonist added to insulin versus basal-plus/basal-bolus insulin in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(3):636–44.
Downloads
Posted
Categories
License
Copyright (c) 2025 Rithvik Hegde
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
